Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP3A5 Genotype on Maraviroc PK
NCT02625207Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of maraviroc in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ViiV Healthcare. Primary endpoints: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours, Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours and 1 more. Started Nov 2015; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02625207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625207.